Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Gains from Sales and Divestitures (2021 - 2024)

Historic Gains from Sales and Divestitures for Apellis Pharmaceuticals (APLS) over the last 4 years, with Q4 2024 value amounting to $1.4 million.

  • Apellis Pharmaceuticals' Gains from Sales and Divestitures rose 3980.3% to $1.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.4 million, marking a year-over-year increase of 3980.3%. This contributed to the annual value of $1.4 million for FY2024, which is 3980.3% up from last year.
  • Apellis Pharmaceuticals' Gains from Sales and Divestitures amounted to $1.4 million in Q4 2024, which was up 3980.3% from $1.0 million recorded in Q4 2023.
  • Apellis Pharmaceuticals' Gains from Sales and Divestitures' 5-year high stood at $1.4 million during Q4 2024, with a 5-year trough of $129000.0 in Q4 2021.
  • For the 4-year period, Apellis Pharmaceuticals' Gains from Sales and Divestitures averaged around $732500.0, with its median value being $691000.0 (2022).
  • In the last 5 years, Apellis Pharmaceuticals' Gains from Sales and Divestitures surged by 18449.61% in 2022 and then surged by 3980.3% in 2024.
  • Over the past 4 years, Apellis Pharmaceuticals' Gains from Sales and Divestitures (Quarter) stood at $129000.0 in 2021, then soared by 184.5% to $367000.0 in 2022, then surged by 176.57% to $1.0 million in 2023, then soared by 39.8% to $1.4 million in 2024.
  • Its Gains from Sales and Divestitures was $1.4 million in Q4 2024, compared to $1.0 million in Q4 2023 and $367000.0 in Q4 2022.